NEW YORK, July 9 - Having raised $43 million in a private placement, Signature Bioscience now hopes to complete its transition from early-stage technology company to provider of drug discovery services, CEO Mark McDade told GenomeWeb Monday.
Already have a GenomeWeb or 360Dx account?Login Now.
What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.
A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.
Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.
In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.